We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is NPCE Worth Buying Now as Growth Potential Meets Execution Risk?
Read MoreHide Full Article
Key Takeaways
NPCE trades at 2.29X forward sales, below industry and historical benchmarks, despite ongoing losses.
NeuroPace's Q3 RNS revenues rose 1.4% as staffing shortages and field transitions disrupted procedures.
NPCE targets 15% core RNS revenue growth in 2027, but pipeline approvals and execution remain uncertain.
NeuroPace, Inc. (NPCE - Free Report) presents a mixed investment setup after third-quarter 2026 results exposed weaker implant activity and commercial disruption. The shares also trade at a discount to key sales-multiple benchmarks, while the company continues to invest behind broader RNS System adoption and new indications.
The debate centers on whether NeuroPace can convert expanding physician interest and its product pipeline into more consistent procedure growth without extending losses or facing further regulatory delays.
NPCE’s Valuation Discount Looks Tempting but Incomplete
NPCE trades at 2.29X forward 12-month sales, below the Zacks sub-industry multiple of 4.65X and its five-year median of 3.46X. That discount may attract investors looking for recovery potential after the shares declined sharply over the past year.
Still, valuation alone does not settle the case. NPCE carries a Value Score of D, indicating that its broader value profile is less favorable despite the lower forward sales multiple. Ongoing losses and uneven revenue growth also limit the usefulness of a simple relative-multiple argument.
Image Source: Zacks Investment Research
NeuroPace Offers Growth Through Broader RNS Adoption
NeuroPace continues to expand its prescriber base and reported another high in active prescribers during the third quarter. The company is also building relationships with community neurologists, Level 3 epilepsy programs and midsized accounts to widen patient identification beyond its traditional dependence on high-volume Level 4 centers.
Established reimbursement supports that effort. Commercial payors had positive coverage policies addressing more than 200 million covered lives as of Dec. 31, 2025, while Medicare and Medicaid routinely provide coverage. In the broader neuromodulation market, Medtronic plc (MDT - Free Report) offers deep brain stimulation for certain adults with drug-resistant partial-onset epilepsy, while LivaNova PLC (LIVN - Free Report) markets VNS Therapy for refractory partial-onset seizures in patients aged four years and older.
NPCE Must Repair Commercial Execution After Q3 Weakness
Third-quarter results showed the gap between physician engagement and completed procedures. RNS System revenues rose just 1.4% year over year to $22.9 million, while total revenues fell 1.1% to $23.1 million.
Management cited staffing shortages, physician availability, diagnostic capacity constraints and field-role transitions at several major accounts. The exit from the SEEG distribution business also reduced routine neurosurgeon engagement. NeuroPace now expects the recovery to develop over several quarters, making referral conversion and field productivity central to the near-term outlook.
Image Source: Zacks Investment Research
NeuroPace’s Pipeline Adds Upside and Timing Risk
ECoG Assistant, Remote Care, idiopathic generalized epilepsy expansion and the AURORA adolescent program could broaden the RNS platform over time. Remote Care has been submitted for FDA review, with possible approval in the second quarter of 2027, subject to the agency’s review.
For idiopathic generalized epilepsy, NeuroPace expects to submit an amendment around year-end 2026 and views potential approval by mid-2027 as a reasonable planning assumption. AURORA is intended to support a possible adolescent focal epilepsy submission in 2027. Each program adds opportunity, but regulatory timing, evidence requirements and physician adoption remain execution variables.
NPCE’s Scores Point to Growth With Valuation Caution
The bottom line is that NPCE offers meaningful growth avenues, but the investment case still depends on better commercial consistency. Management expects approximately 15% core RNS revenue growth in 2027, accelerating toward 20% by year-end, but that outlook excludes any contribution from idiopathic generalized epilepsy.
Its Growth Score of B and Momentum Score of A are favorable, while the Value Score of D and VGM Score of C are less supportive. Zacks Style Scores are designed to complement the Zacks Rank, and the current combination points to growth and momentum strengths without a clear across-the-board signal for a more aggressive stance.
Image: Shutterstock
Is NPCE Worth Buying Now as Growth Potential Meets Execution Risk?
Key Takeaways
NeuroPace, Inc. (NPCE - Free Report) presents a mixed investment setup after third-quarter 2026 results exposed weaker implant activity and commercial disruption. The shares also trade at a discount to key sales-multiple benchmarks, while the company continues to invest behind broader RNS System adoption and new indications.
The debate centers on whether NeuroPace can convert expanding physician interest and its product pipeline into more consistent procedure growth without extending losses or facing further regulatory delays.
NPCE’s Valuation Discount Looks Tempting but Incomplete
NPCE trades at 2.29X forward 12-month sales, below the Zacks sub-industry multiple of 4.65X and its five-year median of 3.46X. That discount may attract investors looking for recovery potential after the shares declined sharply over the past year.
Still, valuation alone does not settle the case. NPCE carries a Value Score of D, indicating that its broader value profile is less favorable despite the lower forward sales multiple. Ongoing losses and uneven revenue growth also limit the usefulness of a simple relative-multiple argument.
Image Source: Zacks Investment Research
NeuroPace Offers Growth Through Broader RNS Adoption
NeuroPace continues to expand its prescriber base and reported another high in active prescribers during the third quarter. The company is also building relationships with community neurologists, Level 3 epilepsy programs and midsized accounts to widen patient identification beyond its traditional dependence on high-volume Level 4 centers.
Established reimbursement supports that effort. Commercial payors had positive coverage policies addressing more than 200 million covered lives as of Dec. 31, 2025, while Medicare and Medicaid routinely provide coverage. In the broader neuromodulation market, Medtronic plc (MDT - Free Report) offers deep brain stimulation for certain adults with drug-resistant partial-onset epilepsy, while LivaNova PLC (LIVN - Free Report) markets VNS Therapy for refractory partial-onset seizures in patients aged four years and older.
NPCE Must Repair Commercial Execution After Q3 Weakness
Third-quarter results showed the gap between physician engagement and completed procedures. RNS System revenues rose just 1.4% year over year to $22.9 million, while total revenues fell 1.1% to $23.1 million.
Management cited staffing shortages, physician availability, diagnostic capacity constraints and field-role transitions at several major accounts. The exit from the SEEG distribution business also reduced routine neurosurgeon engagement. NeuroPace now expects the recovery to develop over several quarters, making referral conversion and field productivity central to the near-term outlook.
Image Source: Zacks Investment Research
NeuroPace’s Pipeline Adds Upside and Timing Risk
ECoG Assistant, Remote Care, idiopathic generalized epilepsy expansion and the AURORA adolescent program could broaden the RNS platform over time. Remote Care has been submitted for FDA review, with possible approval in the second quarter of 2027, subject to the agency’s review.
For idiopathic generalized epilepsy, NeuroPace expects to submit an amendment around year-end 2026 and views potential approval by mid-2027 as a reasonable planning assumption. AURORA is intended to support a possible adolescent focal epilepsy submission in 2027. Each program adds opportunity, but regulatory timing, evidence requirements and physician adoption remain execution variables.
NeuroPace, Inc. Price and Consensus
NeuroPace, Inc. price-consensus-chart | NeuroPace, Inc. Quote
NPCE’s Scores Point to Growth With Valuation Caution
The bottom line is that NPCE offers meaningful growth avenues, but the investment case still depends on better commercial consistency. Management expects approximately 15% core RNS revenue growth in 2027, accelerating toward 20% by year-end, but that outlook excludes any contribution from idiopathic generalized epilepsy.
NPCE currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Its Growth Score of B and Momentum Score of A are favorable, while the Value Score of D and VGM Score of C are less supportive. Zacks Style Scores are designed to complement the Zacks Rank, and the current combination points to growth and momentum strengths without a clear across-the-board signal for a more aggressive stance.